Myelodysplastic Syndrome
Conference Coverage
‘Superior’ CLL regimen cuts chemo in half
Where chemo is still used to treat CLL, this three-cycle regimen combined with ibrutinib and obinutuzumab shows progression-free and overall...
Conference Coverage
‘Extremely exciting’ study results guide MM treatment options
New trial data help inform the tailoring of effective treatment approaches for patients with newly diagnosed multiple myeloma (MM).
Rare Diseases Report 2021
Precision medicine: A new approach to AML, other blood cancers
Precision medicine makes groundbreaking strides in treating myeloid malignancies by integrating individual molecular data into patient care.
Conference Coverage
Myeloid patients respond robustly to Moderna COVID vaccine
Among 46 patients, nearly all seroconverted after second shot.
Conference Coverage
For leukemias, COVID-19 death risks tied to poor prognoses, ICU deferrals
COVID-19 death risks for acute leukemias were driven by poor physician-assessed prognoses and opting out of recommended ICU care.
Conference Coverage
Genotype, need for transfusion predict death in VEXAS syndrome
Among patients with a methionine-to-valine substitution in the UBA1 gene, survival was significantly worse, compared with patients with two other...
Feature
VEXAS: A novel rheumatologic, hematologic syndrome that’s making waves
Conference Coverage
Omidubicel improves on umbilical cord blood transplants
Conference Coverage
Using engineered T cells reduced acute, chronic GVHD
Conference Coverage
Chronic GVHD therapies offer hope for treating refractory disease
From the Journals
Extended virus shedding after COVID-19 in some patients with cancer
Some patients, including stem cell transplant and CAR T recipients, may require extended periods of isolation.